References

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

10.1001/jamaoncol.2024.0985 · ExternalCitation · doi-reference

Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML with Mutated NPM1

10.1002/ajh.26730 · ExternalCitation · doi-reference

Comparison of the International Consensus and 5th WHO Edition Classifications of Adult Myelodysplastic Syndromes and Acute Myeloid Leukemia

10.1002/ajh.26812 · ExternalCitation · doi-reference

Mutant NPM1: Nuclear Export and the Mechanism of Leukemogenesis

10.1002/ajh.26862 · ExternalCitation · doi-reference

Starry Sky Pattern Predicts RAS Pathway Activation in NPM1 -mutated Acute Myeloid Leukemia

10.1002/ajh.27415 · ExternalCitation · doi-reference

NPM1-Mutated Myeloid Neoplasms Are a Unique Entity Not Defined by Bone Marrow Blast Percentage

10.1002/cncr.35433 · ExternalCitation · doi-reference

Impact of Myelodysplasia-related and Additional Gene Mutations in Intensively Treated Patients with NPM1-mutated AML

10.1002/hem3.70060 · ExternalCitation · doi-reference

Venetoclax plus Azacitidine as Genetic-Driven Bridge-to-Transplant Therapy for IDH2-Mutated Acute Myeloid Leukaemia (AML) Refractory to Intensive Chemotherapy: Proof-of-Concept Case Reports

10.1007/s00277-025-06500-0 · ExternalCitation · doi-reference

New Insights into the Biology of Acute Myeloid Leukemia with Mutated NPM1

10.1007/s12185-018-02578-7 · ExternalCitation · doi-reference

Major Nucleolar Proteins Shuttle between Nucleus and Cytoplasm

10.1016/0092-8674(89)90241-9 · ExternalCitation · doi-reference

Mutant NPM1 Maintains the Leukemic State through HOX Expression

10.1016/j.ccell.2018.08.005 · ExternalCitation · doi-reference

Effect of Gemtuzumab Ozogamicin on Survival of Adult Patients with De-Novo Acute Myeloid Leukaemia (ALFA-0701): A Randomised, Open-Label, Phase 3 Study

10.1016/s0140-6736(12)60485-1 · ExternalCitation · doi-reference

Quizartinib plus Chemotherapy in Newly Diagnosed Patients with FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia (QuANTUM-First): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

10.1016/s0140-6736(23)00464-6 · ExternalCitation · doi-reference

Molecular Monitoring versus Standard Clinical Care in Younger Adults with Acute Myeloid Leukaemia: Results from the UK NCRI AML17 and AML19 Randomised, Controlled, Phase 3 Trials

10.1016/s2352-3026(25)00037-7 · ExternalCitation · doi-reference

Pretransplant NPM1 MRD Levels Predict Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

10.1038/bcj.2016.46 · ExternalCitation · doi-reference

Altered Nucleophosmin Transport in Acute Myeloid Leukaemia with Mutated NPM1: Molecular Basis and Clinical Implications

10.1038/leu.2009.124 · ExternalCitation · doi-reference

NPMc+ and FLT3_ITD Mutations Cooperate in Inducing Acute Leukaemia in a Novel Mouse Model

10.1038/leu.2013.114 · ExternalCitation · doi-reference

A Powerful Molecular Synergy between Mutant Nucleophosmin and Flt3-ITD Drives Acute Myeloid Leukemia in Mice

10.1038/leu.2013.77 · ExternalCitation · doi-reference

Activity of a Selective Inhibitor of Nuclear Export, Selinexor (KPT-330), against AML-Initiating Cells Engrafted into Immunosuppressed NSG Mice

10.1038/leu.2015.194 · ExternalCitation · doi-reference

KPT-8602, a Second-Generation Inhibitor of XPO1-Mediated Nuclear Export, Is Well Tolerated and Highly Active against AML Blasts and Leukemia-Initiating Cells

10.1038/leu.2016.145 · ExternalCitation · doi-reference

Mutant Nucleophosmin and Cooperating Pathways Drive Leukemia Initiation and Progression in Mice

10.1038/ng.796 · ExternalCitation · doi-reference

Isocitrate Dehydrogenase 1 and 2 Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia

10.1038/nm.3788 · ExternalCitation · doi-reference

Nucleophosmin and Cancer

10.1038/nrc1885 · ExternalCitation · doi-reference

The Absent/Low Expression of CD34 in NPM1-Mutated AML Is Not Related to Cytoplasmic Dislocation of NPM1 Mutant Protein

10.1038/s41375-022-01593-2 · ExternalCitation · doi-reference

The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

10.1038/s41375-022-01613-1 · ExternalCitation · doi-reference

Venetoclax and Azacitidine for Molecular Relapse after Intensive Chemotherapy in NPM1 or CBF AML: A FILO Study

10.1038/s41408-025-01344-3 · ExternalCitation · doi-reference

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

10.1038/s41409-025-02757-1 · ExternalCitation · doi-reference

Clonal Evolution Patterns in Acute Myeloid Leukemia with NPM1 Mutation

10.1038/s41467-019-09745-2 · ExternalCitation · doi-reference

The AML Cellular State Space Unveils NPM1 Immune Evasion Subtypes with Distinct Clinical Outcomes

10.1038/s41467-025-66546-6 · ExternalCitation · doi-reference

MEN1 Mutations Mediate Clinical Resistance to Menin Inhibition

10.1038/s41586-023-05755-9 · ExternalCitation · doi-reference

Integrated Proteogenomic and Metabolomic Profiling of Acute Myeloid Leukemias to Identify Molecular Subtypes and Associated Therapy Targets

10.1038/s43018-026-01175-6 · ExternalCitation · doi-reference

Frequent Co-Expression of the HOXA9 and MEIS1 Homeobox Genes in Human Myeloid Leukemias

10.1038/sj.leu.2401578 · ExternalCitation · doi-reference

Quantitative Assessment of Minimal Residual Disease in Acute Myeloid Leukemia Carrying Nucleophosmin (NPM1) Gene Mutations

10.1038/sj.leu.2404149 · ExternalCitation · doi-reference

Identification and Functional Characterization of a Cytoplasmic Nucleophosmin Leukaemic Mutant Generated by a Novel Exon-11 NPM1 Mutation

10.1038/sj.leu.2404597 · ExternalCitation · doi-reference

Cytoplasmic Localization of NPM in Myeloid Leukemias Is Dictated by Gain-of-Function Mutations That Create a Functional Nuclear Export Signal

10.1038/sj.onc.1209453 · ExternalCitation · doi-reference

Nucleophosmin in Acute Myelogenous Leukemia

10.1056/nejm200504283521719 · ExternalCitation · doi-reference

Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

10.1056/nejmoa041974 · ExternalCitation · doi-reference

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

10.1056/nejmoa074306 · ExternalCitation · doi-reference

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

10.1056/nejmoa1112304 · ExternalCitation · doi-reference

Assessment of Minimal Residual Disease in Standard-Risk AML

10.1056/nejmoa1507471 · ExternalCitation · doi-reference

Genomic Classification and Prognosis in Acute Myeloid Leukemia

10.1056/nejmoa1516192 · ExternalCitation · doi-reference

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

10.1056/nejmoa1614359 · ExternalCitation · doi-reference

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

10.1056/nejmoa1902688 · ExternalCitation · doi-reference

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

10.1056/nejmoa2117344 · ExternalCitation · doi-reference

Meis1a Suppresses Differentiation by G-CSF and Promotes Proliferation by SCF: Potential Mechanisms of Cooperativity with Hoxa9 in Myeloid Leukemia

10.1073/pnas.231115398 · ExternalCitation · doi-reference

Mutant IDH1 Cooperates with NPM1c or FLT3ITD to Drive Distinct Myeloid Diseases and Molecular Outcomes

10.1073/pnas.2415779122 · ExternalCitation · doi-reference

Selinexor in Combination with Decitabine in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Study

10.1080/10428194.2019.1665664 · ExternalCitation · doi-reference

A 2:1 Randomized, Open-Label, Phase II Study of Selinexor vs. Physician’s Choice in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia

10.1080/10428194.2021.1950706 · ExternalCitation · doi-reference

A Venetoclax and Azacitidine Bridge-to-Transplant Strategy for NPM1-Mutated Acute Myeloid Leukaemia in Molecular Failure

10.1111/bjh.18887 · ExternalCitation · doi-reference

Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma

10.1126/science.8122112 · ExternalCitation · doi-reference

Therapeutic Targeting of Preleukemia Cells in a Mouse Model of NPM1 Mutant Acute Myeloid Leukemia

10.1126/science.aax5863 · ExternalCitation · doi-reference

HOXA9 Modulates Its Oncogenic Partner Meis1 to Influence Normal Hematopoiesis

10.1128/mcb.00545-09 · ExternalCitation · doi-reference

Human Histone Chaperone Nucleophosmin Enhances Acetylation-Dependent Chromatin Transcription

10.1128/mcb.25.17.7534-7545.2005 · ExternalCitation · doi-reference

Nucleophosmin Mutations in De Novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution

10.1158/0008-5472.can-05-4316 · ExternalCitation · doi-reference

Born to Be Exported: COOH-Terminal Nuclear Export Signals of Different Strength Ensure Cytoplasmic Accumulation of Nucleophosmin Leukemic Mutants

10.1158/0008-5472.can-07-0273 · ExternalCitation · doi-reference

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia

10.1158/0008-5472.can-14-2200 · ExternalCitation · doi-reference

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

10.1158/1078-0432.ccr-21-3467 · ExternalCitation · doi-reference

Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia

10.1158/2159-8290.cd-22-0366 · ExternalCitation · doi-reference

Criteria for Diagnosis and Molecular Monitoring of NPM1 -Mutated AML

10.1158/2643-3230.bcd-23-0144 · ExternalCitation · doi-reference

Menin Inhibitor MI-3454 Induces Remission in MLL1-Rearranged and NPM1-Mutated Models of Leukemia

10.1172/jci129126 · ExternalCitation · doi-reference

Acute Myeloid Leukemia Bearing Cytoplasmic Nucleophosmin (NPMc+ AML) Shows a Distinct Gene Expression Profile Characterized by up-Regulation of Genes Involved in Stem-Cell Maintenance

10.1182/blood-2005-02-0560 · ExternalCitation · doi-reference

Mutations in Nucleophosmin (NPM1) in Acute Myeloid Leukemia (AML): Association with Other Gene Abnormalities and Previously Established Gene Expression Signatures and Their Favorable Prognostic Significance

10.1182/blood-2005-05-2168 · ExternalCitation · doi-reference

Nucleophosmin Gene Mutations Are Predictors of Favorable Prognosis in Acute Myelogenous Leukemia with a Normal Karyotype

10.1182/blood-2005-06-2248 · ExternalCitation · doi-reference

Prevalence and Prognostic Impact of NPM1 Mutations in 1485 Adult Patients with Acute Myeloid Leukemia (AML)

10.1182/blood-2005-08-3167 · ExternalCitation · doi-reference

Both Carboxy-Terminus NES Motif and Mutated Tryptophan(s) Are Crucial for Aberrant Nuclear Export of Nucleophosmin Leukemic Mutants in NPMc+ AML

10.1182/blood-2005-11-4745 · ExternalCitation · doi-reference

Immunohistochemistry Predicts Nucleophosmin (NPM) Mutations in Acute Myeloid Leukemia

10.1182/blood-2006-03-007013 · ExternalCitation · doi-reference

Mutated Nucleophosmin Detects Clonal Multilineage Involvement in Acute Myeloid Leukemia: Impact on WHO Classification

10.1182/blood-2006-06-026716 · ExternalCitation · doi-reference

Acute Myeloid Leukemia Carrying Cytoplasmic/Mutated Nucleophosmin (NPMc+ AML): Biologic and Clinical Features

10.1182/blood-2006-07-012252 · ExternalCitation · doi-reference

HOXA9 Is Required for Survival in Human MLL-Rearranged Acute Leukemias

10.1182/blood-2007-09-113597 · ExternalCitation · doi-reference

The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes

10.1182/blood-2009-03-209262 · ExternalCitation · doi-reference

Minimal Residual Disease Levels Assessed by NPM1 Mutation-Specific RQ-PCR Provide Important Prognostic Information in AML

10.1182/blood-2009-03-213389 · ExternalCitation · doi-reference

CD34+ Cells from AML with Mutated NPM1 Harbor Cytoplasmic Mutated Nucleophosmin and Generate Leukemia in Immunocompromised Mice

10.1182/blood-2009-08-238899 · ExternalCitation · doi-reference

Multilineage Dysplasia Has No Impact on Biologic, Clinicopathologic, and Prognostic Features of AML with Mutated Nucleophosmin (NPM1)

10.1182/blood-2009-08-240457 · ExternalCitation · doi-reference

Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Is It a Distinct Entity?

10.1182/blood-2010-08-299990 · ExternalCitation · doi-reference

Acute Myeloid Leukemia Ontogeny Is Defined by Distinct Somatic Mutations

10.1182/blood-2014-11-610543 · ExternalCitation · doi-reference

The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia

10.1182/blood-2016-03-643544 · ExternalCitation · doi-reference

A Phase 1 Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia

10.1182/blood-2016-11-750158 · ExternalCitation · doi-reference

Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia

10.1182/blood-2017-04-779405 · ExternalCitation · doi-reference

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

10.1182/blood-2024-198218 · ExternalCitation · doi-reference

FLT3 Inhibition with Midostaurin Offsets Poor Prognosis in NPM1/FLT3/DNMT3a Triple-Mutated AML

10.1182/blood-2025-1672 · ExternalCitation · doi-reference

DNMT3A, NPM1, and FLT3-ITD Triple-Mutated AML Has a Favorable Prognosis in the Era of FLT3 Inhibitors

10.1182/blood-2025-1710 · ExternalCitation · doi-reference

Ziftomenib in Combination with Venetoclax and Azacitidine in Newly Diagnosed NPM1-m Acute Myeloid Leukemia: Phase 1b Results from KOMET-007

10.1182/blood-2025-766 · ExternalCitation · doi-reference

Molecular MRD Status and Outcome after Transplantation in NPM1-Mutated AML

10.1182/blood.2019002959 · ExternalCitation · doi-reference

Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML

10.1182/blood.2019003988 · ExternalCitation · doi-reference

Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients with NPM1-Mutated AML: Results from the AMLSG 09-09 Trial

10.1182/blood.2020005998 · ExternalCitation · doi-reference

Novel NPM1 Exon 5 Mutations and Gene Fusions Leading to Aberrant Cytoplasmic Nucleophosmin in AML

10.1182/blood.2021012732 · ExternalCitation · doi-reference

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating Morphologic, Clinical, and Genomic Data

10.1182/blood.2022015850 · ExternalCitation · doi-reference

Pretransplant FLT3-ITD MRD Assessed by High-Sensitivity PCR-NGS Determines Posttransplant Clinical Outcome

10.1182/blood.2022016567 · ExternalCitation · doi-reference

Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN

10.1182/blood.2022016867 · ExternalCitation · doi-reference

Molecular MRD Is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy

10.1182/blood.2023021579 · ExternalCitation · doi-reference

Postinduction Molecular MRD Identifies Patients with NPM1 AML Who Benefit from Allogeneic Transplant in First Remission

10.1182/blood.2023023096 · ExternalCitation · doi-reference

Epigenetic Regulation of Noncanonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia

10.1182/blood.2023023644 · ExternalCitation · doi-reference

Measurable Residual Disease and Posttransplantation Gilteritinib Maintenance for Patients with FLT3-ITD–Mutated AML

10.1182/blood.2024025154 · ExternalCitation · doi-reference

Genetic Risk Classification for Adults with AML Receiving Less-Intensive Therapies: The 2024 ELN Recommendations

10.1182/blood.2024025409 · ExternalCitation · doi-reference

Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study

10.1182/blood.2025028357 · ExternalCitation · doi-reference

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

10.1182/blood.2025031480 · ExternalCitation · doi-reference

Overcoming Menin Inhibitor Resistance in AML Cells with Combinations Including BET Proteins and a Dual BRG1/BRM Inhibitor

10.1182/blood.2025031486 · ExternalCitation · doi-reference

Prognostic Impact of FLT3-ITD Microclones in Young Adults with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

10.1182/blood.2025032829 · ExternalCitation · doi-reference

The t(5;17) Variant of Acute Promyelocytic Leukemia Expresses a Nucleophosmin-Retinoic Acid Receptor Fusion

10.1182/blood.v87.3.882.bloodjournal873882 · ExternalCitation · doi-reference

Detection of Normal and Chimeric Nucleophosmin in Human Cells

10.1182/blood.v93.2.632 · ExternalCitation · doi-reference

Proteins Encoded by Genes Involved in Chromosomal Alterations in Lymphoma and Leukemia: Clinical Value of Their Detection by Immunocytochemistry

10.1182/blood.v99.2.409 · ExternalCitation · doi-reference

NPM1 Mutations Define a Specific Subgroup of MDS and MDS/MPN Patients with Favorable Outcomes with Intensive Chemotherapy

10.1182/bloodadvances.2018026989 · ExternalCitation · doi-reference

Clinicopathologic and Genetic Characterization of Nonacute NPM1-Mutated Myeloid Neoplasms

10.1182/bloodadvances.2019000090 · ExternalCitation · doi-reference

Molecular Profile of FLT3-Mutated Relapsed/Refractory Patients with AML in the Phase 3 ADMIRAL Study of Gilteritinib

10.1182/bloodadvances.2021006489 · ExternalCitation · doi-reference

Prolonged XPO1 Inhibition Is Essential for Optimal Antileukemic Activity in NPM1-Mutated AML

10.1182/bloodadvances.2022007563 · ExternalCitation · doi-reference

IL-3-Zetakine Combined with a CD33 Costimulatory Receptor as a Dual CAR Approach for Safer and Selective Targeting of AML

10.1182/bloodadvances.2022008762 · ExternalCitation · doi-reference

Measurable Residual Disease Monitoring in AML with FLT3-ITD Treated with Intensive Chemotherapy plus Midostaurin

10.1182/bloodadvances.2024013758 · ExternalCitation · doi-reference

Long-Term Results from the AGILE Study of Azacitidine plus Ivosidenib vs Placebo in Newly Diagnosed IDH1-Mutated AML

10.1182/bloodadvances.2025016399 · ExternalCitation · doi-reference

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML

10.1200/jco-25-01694 · ExternalCitation · doi-reference

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

10.1200/jco.2011.35.0371 · ExternalCitation · doi-reference

Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial

10.1200/jco.2013.54.4973 · ExternalCitation · doi-reference

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

10.1200/jco.22.00715 · ExternalCitation · doi-reference

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

10.1200/jco.23.02474 · ExternalCitation · doi-reference

10.20944/preprints202607.1293.v1

10.20944/preprints202607.1293.v1 · ExternalCitation · doi-reference

Denaturing High-Performance Liquid Chromatography: A Valid Approach for Identifying NPM1 Mutations in Acute Myeloid Leukemia

10.2353/jmoldx.2006.050098 · ExternalCitation · doi-reference

Translocations and Mutations Involving the Nucleophosmin (NPM1) Gene in Lymphomas and Leukemias

10.3324/haematol.11007 · ExternalCitation · doi-reference

NPM1 Mutations and Cytoplasmic Nucleophosmin Are Mutually Exclusive of Recurrent Genetic Abnormalities: A Comparative Analysis of 2562 Patients with Acute Myeloid Leukemia

10.3324/haematol.12153 · ExternalCitation · doi-reference

Cytoplasmic Mutated Nucleophosmin Is Stable in Primary Leukemic Cells and in a Xenotransplant Model of NPMc+ Acute Myeloid Leukemia in SCID Mice

10.3324/haematol.12225 · ExternalCitation · doi-reference

High CD33 Expression Levels in Acute Myeloid Leukemia Cells Carrying the Nucleophosmin (NPM1) Mutation

10.3324/haematol.2011.043786 · ExternalCitation · doi-reference

Gemtuzumab Ozogamicin for de Novo Acute Myeloid Leukemia: Final Efficacy and Safety Updates from the Open-Label, Phase III ALFA-0701 Trial

10.3324/haematol.2018.188888 · ExternalCitation · doi-reference

Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Non-A/B/D NPM1 Mutations by Digital Polymerase Chain Reaction: Feasibility and Clinical Use

10.3324/haematol.2020.260133 · ExternalCitation · doi-reference

10.3390/cancers11091358

10.3390/cancers11091358 · ExternalCitation · doi-reference

10.3390/cancers13030496

10.3390/cancers13030496 · ExternalCitation · doi-reference

10.3390/cancers15041177

10.3390/cancers15041177 · ExternalCitation · doi-reference

10.3390/genes12091426

10.3390/genes12091426 · ExternalCitation · doi-reference

10.3390/ijms21238975

10.3390/ijms21238975 · ExternalCitation · doi-reference